TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Presentation scheduled for Monday, January 13, 2025, at 4:30 PM PTNEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics,...
Year: 2025
Ribometrix Strengthens Leadership, Appoints William S. Marshall, Ph.D., as Chief Executive Officer and Katie Warner, Ph.D., as Chief Scientific Officer
Revolutionary direct RNA-targeting technology opening a new frontier of prohibiting the production of proteins associated with diseaseDURHAM, N.C., Jan. 09,...
Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors
World-renowned researcher brings expertise in obstetrics and gynecology from Yale University to advance Eterna’s lead indication in ovarian cancerCAMBRIDGE, Mass.,...
Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones
MELBOURNE, Australia and SAN FRANCISCO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the...
Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates
New SER-155 Phase 1b study biomarker data in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients demonstrate that SER-155 promoted epithelial...
Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219’s Transformative Potential for CNS Disorders
In the PET trial, RAP-219 achieved and exceeded target receptor occupancy, increasing support for the dosing regimen utilized in the...
Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies
Azenosertib Fast Track Designation granted for Cyclin E1 positive patients by U.S. Food and Drug Administration (FDA) Manuscript focused on role...
Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy
Transaction Expands Climb Bio’s Pipeline of B-cell Targeted Therapeutics to Address Immune-mediated Diseases New Program is a Highly Potent, Fc-engineered...
Teleflex awarded Short Term Central Venous Catheters contract from Vizient
Including market leading Arrow™ CVCs and Arterial CathetersWAYNE, Pa., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a...
Ultimovacs ASA: Notification of major holdings
Oslo, 9 January 2025: Reference is made to the stock exchange notices published by Ultimovacs ASA (the "Company") on (i)...
Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing
Sharing Insights at the 'Italy on the Move' Event and Engaging Investors at Biotech Showcase During JPM Healthcare Week in...
RQ Bio welcomes positive CHMP opinion on Kavigale for prevention of COVID-19 in immunocompromised individuals
RQ Bio welcomes positive CHMP opinion on Kavigale for prevention of COVID-19 in immunocompromised individuals Kavigale (sipavibart; AZD3152) is a...
Primo Partners with SHINE to Advance Precision Cancer Care in Asia-Pacific
Partnership Delivers Advanced Radioligand Treatments Across Asia-Pacific, Expanding Access to Cutting-Edge Cancer Therapies TAIPEI, Taiwan, Jan. 09, 2025 (GLOBE NEWSWIRE)...
KFSHRC’s Study Named Among Top 10 Most Impactful Papers of 2024
RIYADH, Saudia Arabia, Jan. 09, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) has solidified its...
Philips appoints Jie Xue as Chief Business Leader Precision Diagnosis, co-leader of the Diagnosis & Treatment segment, and Özlem Fidanci as Chief of International Region
Jie Xue Özlem Fidanci January 9, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader...
Ultimovacs ASA – Extraordinary General Meeting held on January 9, 2025
Oslo, January 9, 2025: Ultimovacs ASA held its extraordinary general meeting today January 9, 2025. All the matters on the...
MitoRx Therapeutics Expands Leadership Team with Strategic Appointments of Chief Business Officer and Finance Director
OXFORD, United Kingdom, Jan. 09, 2025 (GLOBE NEWSWIRE) -- MitoRx Therapeutics (MitoRx), a platform biotechnology company developing novel mitochondrial-targeted sulfide-donor...
Coave Therapeutics Secures €32 Million ($33 Million) in Series A Financing to Advance its Next-Generation Genetic Medicines
Financing co-led by Novo Holdings A/S and Bpifrance (as part of the InnoBio investment strategy) and joined by leading US...
MONCYTE Health Joins International Consortium for Earlier Diagnosis and Management of Familial Hypercholesterolemia
EUR 7 million Horizon Europe funded FH-EARLY project on world’s most common inherited metabolic disorderHELSINKI, Jan. 09, 2025 (GLOBE NEWSWIRE)...
Bavarian Nordic Launches Planned Share Buy-Back Program of DKK 150 Million
COPENHAGEN, Denmark, January 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a share buy-back program...